Jack Allen

Analyst

Baird

Analyst

Robert W. Baird & Co. (dialing in for Brian Skorney)

Equibles does not estimate personal net worth.

About Jack Allen

Jack Allen is recorded as Analyst at Baird and Analyst at Robert W. Baird & Co. (dialing in for Brian Skorney). Jack Allen has spoken on 9 earnings calls and 3 other investor events across 5 companies, most recently for Cellectis S.A. on September 8, 2026. Those appearances were for Cellectis S.A. (CLLS), Lineage Cell Therapeutics, Inc. (LCTX), Allogene Therapeutics, Inc. (ALLO), Taysha Gene Therapies, Inc. (TSHA) and Acadia Pharmaceuticals Inc (ACAD). The companies whose calls Jack Allen spoke on are classified in the Healthcare sector.

Jack Allen on recent calls

“I guess the first one I wanted to ask was on SEPO and how we should think about the update in the fourth quarter of this year, any additional color you're willing to provide as it relates to the breadth of the update a number of patients and the durability of follow-up there would be great.”

Analyst — Baird, Wells Fargo 21st Annual Healthcare Conference · September 8, 2026

“I want to extend my congratulations to Zach on the new role. Really great to see you on the quarterly call here. My question is around the RMAT and FastTrack designations that you were able to secure over the course of the quarter.”

Analyst — Baird, The Allogene Therapeutics Second Quarter 2026 Conference Call · August 12, 2026

“I guess the first one I wanted to ask was on SEPO and how we should think about the update in the fourth quarter of this year, any additional color you're willing to provide as it relates to the breadth of the update a number of patients and the durability of follow-up there would be great.”

Analyst — Baird, Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026 · June 25, 2026

“I guess the first one I wanted to ask was on SEPO and how we should think about the update in the fourth quarter of this year, any additional color you're willing to provide as it relates to the breadth of the update a number of patients and the durability of follow-up there would be great.”

Analyst — Baird, Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026 · June 25, 2026

“I'll keep the theme going with 329 questions to start, and then I have one on Semicel as well. On 329, I was just hoping you provide some additional color as it relates to how many doses you could escalate the study in and, you know, what the next step might be.”

Analyst — Baird, Allogene Therapeutics, Inc. Q1 FY2026 Earnings Call · May 13, 2026